Bengül Durmaz

Bengül Durmaz

Auto-generated profile, based on publicly available information

Bengül Durmaz

Department of Clinical Microbiology, Yuksek İhtisas University Faculty of Medicine, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Medeniyet Medical Journal
Verified
Journal Article
Open access
BDBengül Durmaz
Bengül Durmaz
OAOlkar Abdulmajed
Olkar Abdulmajed
RDRiza Durmaz
Riza Durmaz
Coronaviruses (CoVs) classified in the Coronaviridae family infect a very large spectrum of vertebrate group. Seven CoVs that cause human disease consist of Alpha-CoVs, which are HCoV-229E, and NL63 and beta-CoVs, which are MERS-CoV, SARS-CoV, HCoV-OC43, HCoV-HKU1, and SARS-CoV-2. SARS-CoV-2 is an enveloped, positive-polarity, single-stranded RNA virus responsible for a new Coronavirus disease 2019 (COVID-19). The mutagenic ability of the SARS-CoV-2 directs its evolution and genome variability, thus allowing viruses to escape from host immunity and develop drug resistance. Tracing viral mutations is also important for the development of new vaccines, antiviral drugs, and diagnostic systems. During replication in the host cell, genomic mutations occur in the virus and these mutations are transferred to new generations. For this reason, systematic monitoring of mutations in the SARS-CoV-2 genome allows observation of the national and international molecular epidemiology of the virus. SARS-CoV-2 spike (S) glycoprotein is vital in the binding of the virus to the host cell receptor that is angiotensin converting-enzyme 2 (ACE2), membrane fusion, vaccine studies and immune response to the virus. Therefore, mutations in the gene encoding the S glycoprotein and especially the possible variations in the receptor binding domain (RBD) in S gene are important issues to be emphasized. In this article, information about the mutations observed in the SARS-CoV-2 S glycoprotein and their possible effects are presented.

23 June 2021 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
BDBengul Durmaz
Bengul Durmaz
OAOlkar Abdulmajed
Olkar Abdulmajed
RDRiza Durmaz
Riza Durmaz
MKMehmet Koroglu
Mehmet Koroglu
OAOguz Arı
Oguz Arı
MKMahmut Tayar Kalciogu
Mahmut Tayar Kalciogu

1 December 2021 in Turkish Archives of Otorhinolaryngology
Verified
Journal Article
Open access
RDRiza Durmaz
Riza Durmaz
BDBengül Durmaz
Bengül Durmaz
OAOğuz Arı
Oğuz Arı
OAOlkar Abdulmajed
Olkar Abdulmajed
SCSerdal Celik
Serdal Celik
MKMahmut Tayar Kalciogu
Mahmut Tayar Kalciogu
No data have yet been published revealing the composition and the diversity of fungal communities (mycobiome) in the human middle ear cavity. The presented study investigated the mycobiome in the middle ear cavities of individuals with healthy middle ears and patients with otitis media with effusion. A total of 77 middle ear and four adenoid samples were collected from 47 individuals (35 children and 12 adults) in Group 1 and from 20 children in Group 2. The mycobiome profile was analyzed with nuclear ribosomal internal transcribed spacer 2 (ITS2) based metabarcoding using an Illumina MiSeq metagenomics kit. ITS2-based metabarcoding detected 14 different genera and 17 different species with a mean relative abundance of ≥1% in the samples analyzed. Mycobiome profile was similar between the adenoid tissue and the middle ear cavity, between Groups 1 and Group 2, and between children and adults. Fusarium, Stemphylium, Candida, and Cladosporium were the most abundant genera detected in all samples. The mean relative abundances of the genera Candida and Fusarium were remarkably higher in Group 2 compared to Group 1. The species Candida glaebosa, Candida cretensis, Aspergillus ruber, Penicillium desertorum, and Rhizopus arrhizus were significantly more abundant in patients with otitis media with effusion (OME), raising the possibility that they affect the pathogenesis of OME.